Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFα in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy

Gynecologic Oncology

Volumn 108, Issue 2, 2008, Pages 421-427

  Bamias, Aristotelis ^a   Koutsoukou, Vasiliki ^a   Terpos, Evangelos ^b   Tsiatas, Marinos L ^a   Liakos, Christina ^a   Tsitsilonis, Ourania ^a   Rodolakis, Alexandros ^a   Voulgaris, Zannis ^a   Vlahos, G ^a   Papageorgiou, Theocharis ^a   Papatheodoridis, G ^a   Archimandritis, A ^a   Antsaklis, A ^b   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

NK like T cells; Ovarian cancer; TNF ; Tregs; VEGF

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; PLATINUM; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CD4+ CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD56; ASCITES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PROGNOSIS; T-LYMPHOCYTES, REGULATORY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38749145575     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.10.018     Document Type: Article

References (46)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., and Thun M.J. Cancer statistics 2003. CA Cancer J Clin 53 (2003) 5-26
2. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
3. du Bois A., Luck H.J., Meier W., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95 (2003) 1320-1329
4. Ozols R.F. Management of advanced ovarian cancer consensus summary. Semin Oncol 27 Suppl 7 (2000) 47-49
5. Holschneider C.H., and Berek J.S. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19 (2000) 3-10
6. Zhang L., Conejo-Garcia J., Katsaros D., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003) 203-213
7. Sato E., Olson S.H., Ahn J., et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favourable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102 (2005) 18538-18543
8. Curiel T.J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10 (2004) 942-949
9. Straub G., Guckel B., Wallwiener D., and Moldenhauer G. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3. Clin Cancer Res 5 (1999) 171-180
10. Woo E.Y., Chu C., Goletz T.J., et al. Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61 (2001) 4766-4772
11. Bamias A., Tsiatas M.L., Kafantari E., et al. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance. Gynecol Oncol 106 (2007) 75-81
12. Evans C., Dalgleish A.G., and Kumar D. Review article: immune suppression and colorectal cancer. Aliment Pharmacol Ther 24 (2006) 1163-1177
13. Kim R., Emi M., and Tanabe K. Cancer immunosuppression and autoimmune disease: beyond immunosuppressive network for tumor immunity. Immunology 119 (2006) 254-264
14. Barnett B., Kryczek I., Cheng P., Zou W., and Curiel T.J. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 54 (2005) 369-377
15. Zeimet A.G., Widschwendter M., Knabbe C., et al. Ascitic Interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 16 (1998) 1861-1868
16. Chen J.J.W., Yao P.L., Yuann A., et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patients survival in non-small cell lung cancer. Clin Cancer Res 9 (2003) 729-737
17. Asschert J.G.W., Vellenga E., Hollema H., van der Zee A.G.J., and de Vries E.G.E. Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1b (IL-1b), interleukin-11 (IL-11) and tumor necrosis factor-α (TNF-α) in p53-characterised human ovarian carcinomas. Eur J Cancer 33 (1997) 2246-2251
18. Yoshiji H., Kuriyama S., Hicklin D.J., et al. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology 33 (2001) 841-847
19. Yoneda J., Kuniyashu H., Crispens M.A., Price J.E., Bueanna C.D., and Fidler I.J. Expression of angiogenesis-relate genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 90 (1998) 447-451
20. Ueda M., Terai Y., Kumagai K., et al. Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells. Gynecol Oncol 81 (2001) 162-166
21. Ohm J.E., Gabrilovich D.I., Sempowski G.D., et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101 (2003) 4878-4886
22. Lissoni P., Malugani F., Bonfanti A., et al. Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1. J Biol Regul Homeost Agents 15 (2001) 140-144
23. Dikov M.M., Ohm J.E., Ray N., et al. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol 174 (2005) 215-222
24. Markman M., and Bookman M.A. Second-line treatment of ovarian cancer. Oncologist 5 (2000) 26-35
25. high regulatory T cells. Blood 104 (2004) 895-903
26. Rustin G.J., Quinn M., Thigpen T., et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96 6 (2004) 487-488
27. Pellegrini P., Berghella A.M., Del Beato T., et al. Disregulation in Th1 and Th2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 42 (1996) 1-8
28. Chen C.A., Cheng W.F., Lee C.N., et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol 74 (1999) 235-240
29. Secord A.A., Sayer R., Snyder S.A., et al. The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecol Oncol 94 (2004) 74-79
30. Rudlowski C., Pickart A.K., Fuhljan C., et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 16 Suppl 1 (2006) 183-189
31. Della P.M., Danova M., Rigolin G.M., et al. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicopathological findings. Oncology 68 (2005) 276-284
32. Li B., Lalani A.S., Harding T.C., et al. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 12 (2006) 6808-6816
33. Linn Y.C., and Hui K.M. Cytokine-induced killer cells: NK-like T cells with cytotoxic specificity against leukaemia. Leuk Lymphoma 44 (2003) 1457-1462
34. Leemhuis T., Wells S., Scheffold C., Edinger M., and Negrin R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transpl 11 (2005) 181-187
35. Broxmeyer H.E., Cooper S., Li Z.H., et al. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int J Haematol 62 (1995) 203-207
36. Hu L., Hofmann J., Holash J., Yancopoulos G.D., Sood A.K., and Jaffe R.B. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 11 (2005) 6966-6971
37. Wright J.D., Hagemann A., Rader J.S., et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma. A retrospective analysis. Cancer 107 (2006) 83-89
38. Cesana G.C., DeRaffelle G., Cohen S., et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24 (2006) 1169-1177
39. Goldstein I., Ben-Horin S., Koltakov A., et al. Alpha1beta1 integrin+ and regulatory Foxp3+ T cells constitute two functionally distinct human CD4+ T cell subsets oppositely modulated by TNFalpha blockade. J Immunol 178 (2007) 201-210
40. Wu S., Boyer C.M., Whitaker R.S., et al. Tumor necrosis factor a as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor-α expression. Cancer Res 53 (1993) 1939-1944
41. Naylor M.S., Stamp G.W., Foulkes W.D., Eccles D., and Balkwill FR. Tumor necrosis factor and its receptors in human ovarian cancer: potential role in disease progression. J Clin Invest 91 (1993) 2194-2296
42. Kusuda T. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep 13 (2005) 1153-1158
43. Zanin-Zhorov A., Cahalon L., Tal G., Margalit R., Lider O., and Cohen I.R. Heat shock protein 60 enhances CD4+ CD25+ regulatory T cell function via innate TLR2 signaling. J Clin Invest 116 (2006) 2022-2032
44. Goldstein I., Ben-Horin S., Koltakov A., et al. Alpha1beta1 integrin+ and regulatory Foxp3+ T cells constitute two functionally distinct human CD4+ T cell subsets oppositely modulated by TNFalpha blockade. J Immunol 178 1 (Jan 1 2007) 201-210
45. Uslu R., and Bonavida B. Involvement of the mitochondrion respiratory chain in the synergy achieved by the treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-α and cis-diamminedichloroplatinum. Cancer 77 (1996) 725-732
46. Sacchi A., Gasparri A., Gallo-Stampino C., Toma S., Curnis F., and Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-α. Clin Cancer Res 12 (2006) 175-182